ReviewBiomolecules2026
From Insulin Resistance to Mitochondrial Failure: A Staged Model of Impaired Metabolic Flexibility in Schizophrenia.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a highly heritable neuropsychiatric disorder whose pathophysiology remains poorly understood. While neurotransmitter, neurodevelopmental, synaptic, and dysconnectivity hypotheses explain important aspects of the disorder, growing evidence suggests that metabolic dysfunction also plays a central role. This narrative review synthesises evidence from genetics, cell signalling, molecular neuroscience, and metabolism to propose a theoretical framework linking insulin resistance and mitochondrial dysfunction to schizophrenia. We argue that genetic susceptibility and environmental risk factors converge to produce insulin resistance, impaired insulin signalling, and chronic metabolic stress. Reduced insulin signalling suppresses PI3K/AKT activity, while nutrient overload initially hyperactivates mTORC1 independently of PI3K/AKT. Together, these abnormalities shift cellular metabolism away from oxidative metabolism, promote neuroinflammation, impair mitophagy, disrupt mitochondrial dynamics, and increase oxidative stress. Progressive mitochondrial dysfunction subsequently reduces ATP production and downregulates mTORC1, resulting in persistent bioenergetic impairment. We propose that these metabolic abnormalities provide mechanistic links to hallmark features of schizophrenia, including GABAergic and dopaminergic dysfunction, abnormal neurodevelopment, synaptic pathology, cortical structural changes, and disrupted brain connectivity. Finally, we suggest that schizophrenia differs from mood disorders through greater prenatal neurodevelopmental disruption and reduced mitochondrial repair capacity, producing more severe and persistent metabolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.